Replies to post #10417 on RespireRx Pharmaceuticals Inc (RSPI)

[Aiming4]

It's hard to imagine Cephalon is not *extremely* interested in CX717 for RD.

Would Ceph be willing to wait for a CX717 successor to be brought along for RD, or will Ceph be willing to outbid the (presumably multiple) ADHD-interested BPs for CX717?

I guess it depends on who is willing to wait longer for the next Ampakine in the pipeline, and who's willing to pay the most for the privilege of licensing Cortex's lead Ampakine, CX717.

And Neuro's idea of resurrection CX516 for RD could come into play as well.

I wonder if testing CX516 is part of the gameplan early next year for the RD trials... I hope so.

[Fred Kadiddlehopper]

>>>>Thanks Fred, I was looking at the article in #Msg-23231504 which was more generic about the causes:<<<<

No problem, Aiming. I actually read the full version earlier today and I was alarmed when you asked me for a citation and I couldn't find the mention of RD that I was sure I had seen earlier. LOL

So, is this an indication of a potential partnership or just a pipedream of mine?
-Fritz